← Back to Clinical Trials
Recruiting NCT06123325

NCT06123325 Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06123325
Status Recruiting
Phase
Sponsor Montefiore Medical Center
Condition Anxiety Depression
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2023-12-01
Primary Completion 2026-09

Trial Parameters

Condition Anxiety Depression
Sponsor Montefiore Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2023-12-01
Completion 2026-09
Interventions
ClippingEndovascular embolizationSurveillance imaging

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The impact of cerebrovascular procedures on patients experiencing anxiety and depression is not well studied despite the high prevalence of these mental health disorders. Unruptured Intracranial aneurysms (UIAs) have a prevalence of approximately 3% and an annual risk of 1-2% in the general population. Despite the high risk of fatality following aneurysm rupture with a rate of 40-50%, the overall aneurysm growth and rupture risks are rare (less than 3% per aneurysm per year) and many patients can be observed with serial follow-up imaging over years. Nevertheless, due to the gravity of the bad consequences of aneurysm rupture, simply informing many patients of UIA diagnosis has been found to result in worse outcomes of health-related quality of life. This study aims to investigate the impact of awareness of untreated UIA on the patients' mental health utilizing the Hospital Anxiety and Depression Scale (HADS) tool.

Eligibility Criteria

Inclusion Criteria: * Unruptured intracranial aneurysms (UIA) * mRS scores between 0-1 * Observation Group: All patients with UIAs that are eligible for conservative management 1. Specific locations that are not good candidates for interventional treatment, such as cavernous internal carotid artery and very distally located aneurysms 2. Aneurysm size (largest dimension) is less than 4 mm * Treatment Group: All patients with UIAs that are decided to be treated either with endovascular or microsurgical treatments due to several reasons, such as aneurysm size above 4 mm, patient's decision Exclusion Criteria: * Prior history of Subarachnoid Hemorrhage (SAH) * Prior history of intracranial aneurysm * Severe comorbidities that impact the mental health of the patients, such severe psychiatric disease, and chronic end stage diseases * Traumatic, mycotic, dissecting, or fusiform aneurysms * Patients with communication barriers (does not include foreign language), developmental disability, or p

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology